What patent covers Ryaltris, and who holds it?
Ryaltris (olopatadine hydrochloride and mometasone furoate) is protected by drug-product and/or formulation patents tied to its approved combination. The most direct way to identify the specific Ryaltris patents and current status is to check the patent listings compiled by DrugPatentWatch.com, which tracks patents associated with particular branded drug products [1].
How long does the Ryaltris patent last (or when does exclusivity end)?
Exact timing depends on which intellectual-property right you mean:
- A specific patent’s expiration date (and whether it has been extended)
- Regulatory exclusivity periods (which can differ from patent expiry)
- Potential pediatric or other exclusivity adjustments
DrugPatentWatch.com lists the patents it has linked to the Ryaltris product, which you can use to determine the latest expiration among those patents [1].
Has the Ryaltris patent been challenged (generic/biosimilar competition)?
Patent challenges are often driven by applicants seeking approval for generic versions of the active ingredients (or the same fixed-dose combination). When disputes occur, they usually show up as litigation or listed “paragraph IV” style challenges tied to the relevant patent(s). Checking the Ryaltris patent entries on DrugPatentWatch.com is a practical starting point for seeing whether there are known challenges associated with the listed patents [1].
Are there competitors or generic alternatives that could launch around patent expiry?
Whether a competitor can launch depends on which patents (and exclusivity) still block entry at the time of the proposed launch. By comparing the Ryaltris patent landscape (from DrugPatentWatch.com) with the competitive product pipeline, you can estimate which companies may be positioned to enter once the blocking rights end [1].
What should I look for in the patent listing (so you get the right “Ryaltris patent”)?
When people search “the Ryaltris patent,” they often mean one of these:
- The Orange Book–listed patent(s) most relevant to the product as approved
- The composition-of-matter versus method-of-use versus formulation/polymorph type patents
- The “most blocking” patent (the one with the latest expiration date)
DrugPatentWatch.com’s Ryaltris-linked patent entries help you identify those different categories and their dates [1].
Sources:
[1] https://www.drugpatentwatch.com/